



Stephan R Vavricka

Contact

Stephan R Vavricka

Publications (20)

Kueres-Wiese A, Vavricka S, Baumann P. Probiotika in der Gastroenterologie. *Swiss Med Forum* 2023; 2023:1482-1487.

Perrig K, Krupka N, Jordi S, Rossel J, Biedermann L, Greuter T, Schreiner P, Vavricka S, Juillerat P, Burri E, Zimmermann D, Maillard M, Sulz M, Brand S, Rogler G, Misselwitz B. Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. *Therap Adv Gastroenterol* 2022; 15:17562848221074188.

Schreiner P, Misselwitz B, von Känel R, Rogler G, Juillerat P, Pittet V, Vavricka S, Scharl M, Greuter T, Baumann C, Valko P, Biedermann L, Rossel J, Swiss IBD Cohort Study Group. Fatigue in inflammatory bowel disease and its impact on daily activities. *Aliment Pharmacol Ther* 2020; 53:138-149.

Schreiner P, Rogler G, Juillerat P, Vavricka S, Vulliemoz M, Restellini S, Schoepfer A, Michetti P, Brand S, Maillard M, Fehr J, Mueller N, Biedermann L. Varicella zoster virus in inflammatory bowel disease patients: what every gastroenterologist should know. *J Crohns Colitis* 2020

Greuter T, Vavricka S, Biedermann L, Pilz J, Borovicka J, Seibold F, Sauter B, Rogler G. Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. *Dig Dis* 2017

Vavricka S, Biedermann L, Michetti P, Straumann A, Misselwitz B, Scharl M, Manser C, Greuter T, Zeitz J, Frei P, Borovicka J, Seibold F, Schoepfer A, Rogler G, Spasojevic M. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey. *Dig Dis* 2017; 35:423-432.

Vavricka S, Misselwitz B, Scharl M, Heinrich H, Manser C, Safroneeva E, Raja Ali R, Rogler G, Schoepfer A, Greuter T, Zeitz J, Biedermann L, Juillerat P, Gubler M, Gantenbein C, Spoerri M, Froehlich F, Seibold F, Protic M, Michetti P, Straumann A, Fournier N. Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study. *Inflamm Bowel Dis* 2017

Zeitz J, Rogler G, Fried M, Sulz M, Vavricka S, Scharl S, Misselwitz B, Frei P, Biedermann L, Labenz C, Fournier N, Scharl M. Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. *Inflamm Intest Dis* 2017; 1:172-181.

Bontà J, Rogler G, Fried M, Scharl S, Vavricka S, Sulz M, Biedermann L, Frei P, Zeitz J, Scharl M. Cytomegalovirus disease in inflammatory bowel disease: epidemiology and disease characteristics in a large single-centre experience. *Eur J Gastroenterol Hepatol* 2016; 28:1329-34.

Spalinger M, Scharl M, Rogler G, Fried M, Vavricka S, Scharl S, Frei P, Sulz M, Rossel J, Biedermann L, Zeitz J. Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. *PloS one* 2016; 11:e0160215.

Madanchi M, Rogler G, Vavricka S, Frei P, Biedermann L, Sulz M, Scharl S, Samaras P, Barthel C, Zeitz J, Scharl M. Malignancies in Patients with Inflammatory Bowel Disease: A Single-Centre Experience. *Digestion* 2016; 94:1-8.

Vögelin M, Rogler G, Fried M, Sulz M, Zeitz J, Scharl S, Vavricka S, Frei P, Biedermann L, Scharl M. The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. *PloS one* 2016; 11:e0155218.

Spalinger M, Scharl M, Rogler G, Fried M, Vavricka S, Scharl S, Frei P, Sulz M, Rossel J, Zeitz J, Biedermann L, Voegelin M. The Clinical Relevance of the IBD-Associated Variation within the Risk Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 2 in Patients of the Swiss IBD Cohort. *Digestion* 2016; 93:182-92.

Vavricka S, Rogler G, Safroneeva E, Peter S, Beglinger C, Biedermann L, Manz M, Rechner R, Degen L, Sulz M, Schoepfer A. Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists. *Endoscopy* 2016

Manser C, Borovicka J, Seibold F, Vavricka S, Lakatos P, Fried M, Rogler G. Risk factors for complications in patients with ulcerative colitis. *United European Gastroenterol J* 2016; 4:281-7.

Barthel C, Rogler G, Wiegand N, Sulz M, Fried M, Vavricka S, Frei P, Scharl M, Scharl S, Wiegand S, Biedermann L. Patients' perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe?--a patient survey. *Nutr J* 2015; 14:78.

Sulz M, Sagmeister M, Meyenberger C, Vavricka S, von Känel R, Wurm J, Gothe R, Arvandi M, Siebert U, Swiss IBD Cohort Study Group. Predictors for hospitalization and outpatient visits in patients with inflammatory bowel disease: results from the Swiss Inflammatory Bowel Disease Cohort Study. *Eur J Gastroenterol Hepatol* 2013; 25:790-7.

Siebert U, Sagmeister M, Meyenberger C, Sulz M, Bègré S, von Känel R, Vavricka S, Arvandi M, Gothe R, Wurm J, the Swiss IBD Cohort Study Group. Predictors of Temporary and Permanent Work Disability in Patients With Inflammatory Bowel Disease: Results of the Swiss Inflammatory Bowel Disease Cohort Study. *Inflamm Bowel Dis* 2013; 19:847-855.

Vavricka S, Michetti P, Straumann A, Seibold F, Scharl M, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Banský G, Schoepfer A, for the Swiss IBDnet. Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey. *Inflamm Bowel Dis* 2010

Schoepfer A, Straumann A, Seibold F, Sauter B, de Saussure P, Rogler G, Manz M, Geyer M, Felley C, Binek J, Vavricka S, Michetti P. Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: Results of the FACTS survey. *Inflammatory bowel diseases* 2009

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch